Anti-CD20 Therapies Decrease Humoral Immune Response to SARS-CoV-2 in Patients With MS or NMOSD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Neurology, Neurosurgery, and Psychiatry
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
J. Neurol. Neurosurg. Psychiatr. 2022 Jan 01;93(1)24-31, C Louapre, M Ibrahim, E Maillart, B Abdi, C Papeix, B Stankoff, AL Dubessy, C Bensa-Koscher, A Créange, Z Chamekh, C Lubetzki, AG Marcelin, JC Corvol, V PourcherFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.